



of Caspofungin in the Treatment of Fungal
Keratitis Refractory to Voriconazole
F ungal keratitis is an important ophthalmic prob-lem because it leads to corneal blindness andsometimes to loss of the eye.1,2 There is no agreed
protocol for the treatment of suspected fungal keratitis.
Topical and oral voriconazole have now been reported
to be effective.3 However, some cases do not respond to
this treatment. New antifungal agents such as caspofun-
gin acetate, 0.5%, are promising alternatives.
Report of a Case. A 60-year-old woman with a history
of penetrating keratoplasty in her right eye due to cor-
neal herpetic infection 1 year earlier was admitted be-
cause of visual disturbances and ocular pain. Slitlamp ex-
amination revealed an epithelial defect with corneal
infiltration (Figure, A). Corneal scrapings were taken
for smear and culture, and Candida albicans was iso-
lated. We asked our pharmacology service for ampho-
tericin B eyedrops but were informed of solubility and
stability problems with the actual presentation of this drug.
Treatment with topical voriconazole, 1%, administered
every hour and oral voriconazole at a dosage of 200 mg
twice daily was started. After 1 month the lesion had not
progressed but there was no change in corneal infiltra-
tion, and cultures remained repeatedly positive for C al-
bicans with no evidence of viral infection (Figure, B).
Therefore, after obtaining the patient’s consent and per-
mission of sanitary authorities, we decided to apply topi-
cal caspofungin, 0.5%, every hour. To obtain the eye-
drops, 1 vial of 50 mg of caspofungin acetate was diluted
in 10.5 mL of sterile normal saline; all eyedrops were
freshly made daily, kept at 4°C, and protected from light.
One week later, clinical improvement was observed and





Figure. Evolution of the case. A, Epithelial defect with corneal infiltration. Corneal scrapings were taken for smear and culture, and Candida albicans was isolated. B,
One month after starting treatment with topical voriconazole, cultures remained positive for C albicans. C, One week after starting treatment with topical caspofungin
acetate, clinical improvement was observed and cultures revealed no growth. D, Four weeks after starting treatment with topical caspofungin, complete healing of the
corneal epithelium and resolution of the corneal infiltrate were observed. However, the corneal opacity persisted (a neglected suture was removed).
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topical caspofungin was progressively decreased over 3
further weeks. Following the completion of treatment,
complete healing of the corneal epithelium and resolu-
tion of the corneal infiltrate were observed, although the
corneal opacity persisted (Figure, D). There was no evi-
dence of ocular toxic effects and no recurrence of fungal
keratitis over a follow-up period of 6 months.
Comment. C albicans is the most frequent cause of fun-
gal keratitis in temperate regions and is an opportunis-
tic organism that can complicate chronic keratopathy
and corneal grafting. Persistent epithelial defects and
suture-related problems, along with immunosuppres-
sion, have been found to be the major predisposing risk
factors.
Caspofungin is a first-in-class echinocandin with po-
tent activity against Candida and Aspergillus, the domi-
nant human fungal pathogens. In contrast to all other an-
tifungal drugs, echinocandins have a selective action on
a target present only in fungal cell walls (not in mam-
malian cells): they inhibit the synthesis of an essential
component, (1,3)-D-glucan. Caspofungin is fungicidal in
vivo and in vitro against all Candida species, including
fluconazole-resistant strains. Its activity differs from that
of the azole antifungal group, which is fungistatic.4 In our
case, we think that voriconazole stopped progression of
the infiltrate but did not kill the microorganism. The pres-
ence of the fungus after 1 month could be due to poor
drug penetration, fungal resistance, or both. We there-
fore suggest that an ideal treatment protocol should in-
clude antifungal agents chosen on the basis of in vitro
susceptibility of the fungus with a duration assessed by
in vivo monitoring of fungal filaments or yeasts.
To our knowledge, the topical ocular use of caspo-
fungin has been reported in rabbits.5 There has been only
1 report of its use in humans, although it was in asso-
ciation with other antifungal drugs.4
In conclusion, topical caspofungin, 0.5%, is a new,
promising option in the treatment of refractory fungal-
related corneal ulcers with no evidence of ocular toxic
effects. However, future studies with larger samples are
indicated to further evaluate its efficacy and tolerance.
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T he coexistence of idiopathic inflammatory massesof the submandibular and lacrimal glands fea-turing lymphoid hyperplasia and fibrosclerosis
is unknown to most ophthalmologists.1-3 The former is
referred to as Küttner tumor. Systemic and autoim-
mune diseases, including Sjögren syndrome (SS) and lym-
phoma, are characteristically absent in this complex. In
our case, IgG4-positive plasma cells were present in the
lesions of both glands.
Report of a Case. A 69-year-old woman had left sub-
mandibular gland swelling that developed over 2 months
in 2002. Biopsy revealed chronic sclerosing sialadenitis.
Recurrence and rebiopsy in 2005 showed the same patho-
logic findings. In 2008, the patient had sudden bulging
of her right eye with lateral eyelid fullness, pain, and
double vision. Best-corrected visual acuities were 20/30
OD and 20/25 OS. The right eye exhibited mild epi-
bulbar injection, painful limited abduction, and 3 mm
of proptosis (Figure 1A). A computed tomographic scan
demonstrated enlargement of the right lacrimal gland and
lateral and superior rectus muscles (Figure 1B). Results
from a general physical examination and standard sero-
logical studies were negative. Serum IgG4 levels were not
obtained. The patient did not have diabetes or abdomi-
nal or urinary tract symptoms, and an abdominal com-
puted tomographic scan was not performed. Biopsy of
the lacrimal gland revealed sclerosing dacryoadenitis. The
patient was treated with a prednisone taper over 2 months
starting at 80 mg daily and decreasing by 10 mg every
week. Seven months later, she manifested a nontender,
palpable lacrimal gland with residual proptosis without
recurrence of submandibular disease. The patient con-
tinued to feel well and no systemic disease has emerged
over a clinical course of 7 years.
The submandibular and lacrimal gland biopsies dis-
played similar histopathologic features. The fibrous septa
in the former were thickened and enclosed lobules of glan-
dular tissue exhibiting a lymphoplasmacytic infiltrate with
scattered follicles (Figure 1C). Interstitial fibrosis and aci-
nar atrophy were juxtaposed with uninvolved lobules of
well-preserved glandular tissue (Figure 1D). A smaller
lacrimal gland biopsy specimen harbored a dense lym-
phoplasmacytic infiltrate (Figure 1E) with rare surviv-
ing acini (Figure 1F). The CD3 T lymphocytes some-
what predominated over CD20 B lymphocytes in the
parotid gland (Figure 2A), whereas the converse was
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